BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Dynatronics Corporation (DYNT) Introduces the Dynatron Quad7 Device


3/13/2012 9:57:33 AM

SALT LAKE CITY, March 12, 2012 /PRNewswire/ -- Dynatronics Corporation (NASDAQ: DYNT) today announced the introduction of the new Dynatron Quad7 therapy device. The innovative Quad7 redefines cold/compression therapy in the sports medicine and physical therapy markets by adding options for heat therapy as well as facilitating thermal therapy in combination with electrical stimulation through the use of proprietary combination probes. The Quad7 has the flexibility to offer seven different treatments leapfrogging current technologies and products in the market.

"We are beginning to enjoy the first fruits of our extensive R&D efforts," stated Kelvyn H. Cullimore Jr., chairman and president of Dynatronics. "The new Quad7 is the first of several new products scheduled for release in 2012. In fact, we now have more new products scheduled for introduction in 2012 than during any year in the company's history. This commitment to R&D further strengthens Dynatronics' long-standing reputation as an innovator and market leader in the development of physical rehab equipment."

The Quad7 delivers therapy treatment through a variety of wraps and innovative ThermoStim Probes. "The addition of manual probes to the package will allow delivery of electrical stimulation, combined with either heat or cold to localized areas," reported Larry K. Beardall, executive vice president of sales and marketing. "This dramatically expands both the variety and location of conditions that can be treated, thus making current delivery methods even more obsolete."

The Dynatron Quad7 uses thermoelectric technology to provide precise temperature control, eliminating the need for ice. "No ice is nice," said Beardall. "Clinicians will love eliminating the hassle and mess of melting ice cubes."

The economic downturn over the past few years has diminished new product development in the physical medicine market. "Our markets are starving for innovative new products. We're thrilled to be in a position to deliver them," added Beardall. "Product availability will be limited in these first few months as we ramp up production, but that should just add to the demand for this unique new device."

Dynatronics manufactures, markets and distributes advanced-technology medical devices, orthopedic soft goods and supplies, treatment tables and rehabilitation equipment for the physical therapy, sports medicine, chiropractic, podiatry, plastic surgery, dermatology and other related medical, cosmetic and aesthetic markets. More information regarding Dynatronics is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and similar statements such as the statement regarding expectations for future new product line introductions. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2011.

SOURCE Dynatronics Corporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES